source
- Agenus redirects late-stage colorectal trial to pre-surgery setting, shares double; Oxford Ebola vaccine enters Phase 1Agenus announced it will stop financially supporting its late-stage trial of the BOT+BAL immunotherapy combination in late-line colorectal cancer. The company will instead use recent $340 million…
- FDA issues final guidance for psychedelic drug developers and announces public hearingThe FDA has completed a set of clinical guidance documents aimed at companies developing psychedelic medicines. The guidance outlines expectations for trial design, safety monitoring, and data col…